The Latest
-
Trump tariffs
Mitigating tariffs: EY’s Lynlee Brown discusses strategies for medtech
Lynlee Brown, a global trade partner at EY, outlined several strategies for device manufacturers to offset fast-moving tariffs.
-
RFK Jr. confirmed as HHS secretary
Robert F. Kennedy Jr., a prominent vaccine critic, was confirmed Thursday by the U.S. Senate in a 52-48 vote to serve as the nation’s top health official.
-
Medtronic buys Nanovis’ nano technology for use in spine implants
Medtronic will use the technology to develop PEEK interbody spine fusion devices that enhance implant fixation.
-
Trump tariffs
How Trump’s trade fight could impact the medtech industry
Relocating manufacturing would require substantial capital investment, but the timespan for the president’s new tariffs is unclear, supply chain experts said.
-
Retrieved from Screenshot: The Food and Drug Administration.
Judge orders FDA, health agencies to restore removed webpages
District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking healthcare.”
-
Trump orders agencies to plan for ‘large-scale’ job cuts
While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health agencies like the FDA.
-
Edwards predicts second-half lift from TAVR label expansion
Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.
-
EMA creates advice portal for some high-risk medical devices
The European Medicines Agency said the portal will enable consultations with medical device expert panels that can promote faster access to new technologies.
-
Inspire Medical reveals DOJ civil investigation
CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January for information on marketing and reimbursement practices.
-
Former FDA head Gottlieb calls for less regulation of certain AI tools
Gottlieb, who led the agency during the first Trump presidency, supports a reversion to an earlier interpretation of the 21st Century Cures Act.